|
🐜
|
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
13 auth.
B. Coiffier,
É. Lepage,
J. Brière,
R. Herbrecht,
H. Tilly,
R. Bouabdallah,
P. Morel,
E. Van Den Neste,
G. Salles,
P. Gaulard,
...
F. Reyes,
P. Lederlin,
C. Gisselbrecht
|
11 |
2002 |
11
🐜
|
|
🐜
|
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B‐Cell Lymphoma
24 auth.
S. Schuster,
M. Bishop,
C. Tam,
E. Waller,
P. Borchmann,
J. Mcguirk,
U. Jäger,
S. Jaglowski,
C. Andreadis,
J. Westin,
...
I. Fleury,
V. Bachanova,
R. Foley,
Joy P. Ho,
S. Mielke,
J. Magenau,
H. Holte,
Serafino Pantano,
L. Pacaud,
R. Awasthi,
J. Chu,
Ö. Anak,
G. Salles,
R. Maziarz
|
11 |
2019 |
11
🐜
|
|
🐜
|
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.
7 auth.
G. Cartron,
L. Dacheux,
G. Salles,
P. Solal-Céligny,
P. Bardos,
P. Colombat,
...
H. Watier
|
10 |
2002 |
10
🐜
|
|
🐜
|
The 2016 revision of the World Health Organization classification of lymphoid neoplasms.
11 auth.
S. Swerdlow,
E. Campo,
S. Pileri,
N. Harris,
H. Stein,
R. Siebert,
...
R. Advani,
M. Ghielmini,
G. Salles,
A. Zelenetz,
E. Jaffe
|
10 |
2016 |
10
🐜
|
|
🐜
|
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
16 auth.
P. Feugier,
A. Hoof,
C. Sebban,
P. Solal-Céligny,
R. Bouabdallah,
C. Fermé,
B. Christian,
É. Lepage,
H. Tilly,
F. Morschhauser,
...
P. Gaulard,
G. Salles,
A. Bosly,
C. Gisselbrecht,
F. Reyes,
B. Coiffier
|
10 |
2005 |
10
🐜
|
|
🐢
|
PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.
22 auth.
A. Gopal,
B. Kahl,
S. de Vos,
N. Wagner-Johnston,
S. Schuster,
W. Jurczak,
I. Flinn,
C. Flowers,
P. Martin,
A. Viardot,
...
K. Blum,
A. Goy,
A. Davies,
P. Zinzani,
M. Dreyling,
D. Johnson,
L. Miller,
Leanne Holes,
Daniel Li,
R. Dansey,
W. Godfrey,
G. Salles
|
9 |
2014 |
9
🐢
|
|
🦁
|
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
30 auth.
G. Salles,
J. Seymour,
F. Offner,
A. López-Guillermo,
D. Belada,
L. Xerri,
P. Feugier,
R. Bouabdallah,
J. Catalano,
P. Brice,
D. Caballero,
C. Haioun,
L. Pedersen,
A. Delmer,
D. Simpson,
...
S. Leppa,
P. Soubeyran,
A. Hagenbeek,
O. Casasnovas,
T. Intragumtornchai,
C. Fermé,
Maria Gomes da Silva,
C. Sebban,
A. Lister,
J. Estell,
G. Milone,
A. Sonet,
M. Mendila,
B. Coiffier,
H. Tilly
|
9 |
2011 |
9
🦁
|
|
🐜
|
The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma.
22 auth.
K. Savage,
S. Monti,
J. Kutok,
G. Cattoretti,
D. Neuberg,
L. de Leval,
P. Kurtin,
P. Dal Cin,
C. Ladd,
F. Feuerhake,
...
R. Aguiar,
Sigui Li,
G. Salles,
F. Berger,
Wen Jing,
G. Pinkus,
T. Habermann,
R. Dalla-Favera,
N. Harris,
J. Aster,
T. Golub,
M. Shipp
|
9 |
2003 |
9
🐜
|
|
🐜
|
The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee.
72 auth.
E. Campo,
E. Jaffe,
J. Cook,
L. Quintanilla‐Martinez,
S. Swerdlow,
K. Anderson,
P. Brousset,
L. Cerroni,
L. de Leval,
S. Dirnhofer,
A. Dogan,
A. Feldman,
F. Fend,
J. Friedberg,
P. Gaulard,
...
P. Ghia,
S. Horwitz,
R. King,
G. Salles,
J. San-Miguel,
J. Seymour,
S. Treon,
J. Vose,
E. Zucca,
R. Advani,
S. Ansell,
W. Au,
C. Barrionuevo,
P. Bergsagel,
W. Chan,
J. Cohen,
A. Davies,
B. Falini,
I. Ghobrial,
J. Goodlad,
J. Gribben,
E. Hsi,
B. Kahl,
W. Kim,
Shaji K. Kumar,
A. LaCasce,
C. Laurent,
G. Lenz,
J. Leonard,
M. Link,
A. López-Guillermo,
M. Mateos,
E. Macintyre,
A. Melnick,
F. Morschhauser,
S. Nakamura,
M. Narbaitz,
A. Pavlovsky,
S. Pileri,
M. Piris,
B. Pro,
S. Rajkumar,
S. Rosen,
B. Sander,
L. Sehn,
M. Shipp,
Sonali M. Smith,
L. Staudt,
C. Thieblemont,
T. Tousseyn,
W. Wilson,
T. Yoshino,
P. Zinzani,
M. Dreyling,
D. Scott,
J. Winter,
A. Zelenetz
|
9 |
2022 |
9
🐜
|
|
🐜
|
Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation.
21 auth.
P. Colombat,
G. Salles,
N. Brousse,
Pitahey Eftekhari,
Piere Soubeyran,
V. Delwail,
E. Deconinck,
C. Haioun,
C. Foussard,
C. Sebban,
...
Astasia Stamatoullas,
N. Milpied,
F. Boué,
B. Taillan,
P. Lederlin,
A. Najman,
C. Thieblemont,
F. Montestruc,
A. Mathieu-Boué,
A. Benzohra,
P. Solal-Céligny
|
9 |
2001 |
9
🐜
|
|
🐜
|
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
150 auth.
S. Horwitz,
O. O’Connor,
B. Pro,
T. Illidge,
M. Fanale,
R. Advani,
N. Bartlett,
J. H. Christensen,
F. Morschhauser,
E. Domingo-Domènech,
G. Rossi,
W. Kim,
T. Feldman,
A. Lennard,
D. Belada,
...
Á. Illés,
K. Tobinai,
K. Tsukasaki,
S. Yeh,
A. Shustov,
A. Hüttmann,
K. Savage,
S. Yuen,
S. Iyer,
P. Zinzani,
Zhaowei Hua,
M. Little,
Shangbang Rao,
J. Woolery,
T. Manley,
L. Trümper,
D. Aboulafia,
O. Alpdogan,
K. Ando,
L. Arcaini,
L. Baldini,
Naresh Bellam,
N. Bartlett,
D. B. Yehuda,
F. Benedetti,
Peter Borchman,
D. Bordessoule,
P. Brice,
J. Briones,
D. Caballero,
A. Carella,
Hung Chang,
June Weon Cheong,
Seok-Goo Cho,
I. Choi,
S. Choquet,
A. Colita,
Angela Giovanna Congui,
F. d'Amore,
N. Dang,
K. Davison,
S. Guibert,
P. Brown,
V. Delwail,
J. Demeter,
F. Raimondo,
Y. Do,
E. Domingo,
Michael G. Douvas,
M. Dreyling,
T. Ernst,
K. Fay,
S. Ferrero,
I. Flinn,
A. Forero-Torres,
C. Fox,
J. Friedberg,
N. Fukuhara,
J. García-Marco,
Jorge Gayoso Cruz,
J. Codina,
R. Gressin,
A. Grigg,
R. Gurion,
C. Haioun,
R. Hájek,
M. Hanel,
K. Hatake,
Rob Hensen,
N. Horowitz,
A. Huttmann,
Á. Illés,
K. Ishizawa,
M. Islas‐Ohlmayer,
E. Jacobsen,
M. Janakiram,
W. Jurczak,
M. Kaminski,
Koji Kato,
I. Kirgner,
C. Kuo,
M. Lazaroiu,
K. Du,
Jong-Seok Lee,
S. Legouill,
P. LaRosée,
I. Levi,
B. Link,
H. Maisonneuve,
D. Maruyama,
J. Mayer,
J. McCarty,
P. McKay,
Y. Minami,
H. Mociková,
E. Morra,
J. Muñoz,
H. Nagai,
O. O'connor,
Stephen Samuel Opat,
R. Pettengell,
A. Pezzutto,
M. Pfreundschuh,
A. Pluta,
P. Porcu,
H. Quach,
A. Rambaldi,
William E. P. Renwick,
Ruben Reyes,
A. Izquierdo,
J. Ruan,
C. Rusconi,
G. Salles,
A. Santoro,
J. Sarriera,
K. Savage,
H. Shibayama,
C. Suh,
A. Sureda,
M. Tanimoto,
M. Taniwaki,
H. Tilly,
M. Trněný,
L. Trumper,
N. Tsukamoto,
U. Vitolo,
J. Walewski,
E. Weidmann,
M. Wilhelm,
M. Witzens‐Harig,
A. Yacoub,
Kazuhito Yamamoto,
S. Yoon,
H. Yun,
J. Zain
|
9 |
2019 |
9
🐜
|
|
🐜
|
Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA).
12 auth.
O. Hermine,
C. Haioun,
É. Lepage,
M. D'agay,
J. Brière,
C. Lavignac,
...
G. Fillet,
G. Salles,
J. Marolleau,
J. Diebold,
F. Reyas,
P. Gaulard
|
8 |
1996 |
8
🐜
|
|
🐜
|
Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study.
15 auth.
C. Haioun,
É. Lepage,
C. Gisselbrecht,
G. Salles,
B. Coiffier,
P. Brice,
A. Bosly,
P. Morel,
C. Nouvel,
H. Tilly,
...
P. Lederlin,
C. Sebban,
J. Brière,
P. Gaulard,
F. Reyes
|
8 |
2000 |
8
🐜
|
|
🦁
|
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
8 auth.
G. Salles,
M. Barrett,
R. Foà,
J. Maurer,
S. O'brien,
N. Valente,
...
M. Wenger,
D. Maloney
|
8 |
2017 |
8
🦁
|
